From the Departments of General Surgery (Drs Machens and Dralle), Pathology (Dr Hinze), and Medical Epidemiology, Biometrics, and Informatics (Dr Lautenschl[[auml]]ger), Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
Insular carcinoma represents a more aggressive subtype of differentiated thyroid cancer on multivariate analysis after controlling for various clinicopathologic parameters.
Tertiary referral center at a university hospital.
One hundred twenty-seven consecutive patients having a histological diagnosis of the follicular variant of papillary thyroid carcinoma or follicular thyroid carcinoma.
Main Outcome Measure
A logistic regression model was used to examine the relationship between various clinicopathologic parameters and the insular subtype.
The insular subtype involved 14 of 127 tumors. Unlike extrathyroidal extension and nodal metastasis, primary tumor diameter (>40 mm vs ≤40 mm; P = .008) and distant metastasis (P = .003) correlated with the insular subtype. Both parameters were interrelated since tumors greater than 40 mm displayed distant metastasis more often (30% vs 8%; P = .008) than tumors measuring 40 mm or less.
These findings suggest that an unidentified somatic event may induce an accelerated proliferation of the transformed thyrocytes, which may ultimately result in enhanced rates of distant metastasis with increasing tumor volume.
SINCE THE seminal description of insular carcinoma by Carcangiu et al in 1984,1 no universal consensus has been reached as to the biological aggressiveness and prognostic relevance of this comparatively rare subtype of thyroid cancer. Some authors have identified significant correlations between insular carcinoma and the occurrences of extrathyroidal growth and nodal metastases.2 These observations are awaiting confirmation by investigations that include an unselected noninsular control group. Many literature reports in this field have been hampered by the lack of such a noninsular control group. Because of the rarity of insular carcinoma—accounting for only 3.8% (27/720) to 6.2% (41/657) of thyroid tumors1- 3—recruiting enough patients with insular carcinoma has posed difficult problems.
More recent publications have addressed the issue of biological aggressiveness by comparing patients with insular carcinoma with control groups composed of patients with more invasive forms of differentiated thyroid carcinoma. These controls have had neoplasms as diverse as widely invasive follicular carcinoma,2,4 the tall cell, and diffuse sclerosing variants of papillary carcinoma.5,6 Owing to the unavailability of an unselected noninsular control group, this approach does not allow one to draw definitive conclusions about the unique oncological properties of the insular subtype. To resolve the issue of biological aggressiveness of insular carcinoma, our institutional investigation was conducted in an unselected cohort of 127 consecutive patients with differentiated thyroid cancer.
From November 1994 through October 1999, a total of 256 consecutive patients at our institution underwent surgery for papillary thyroid carcinoma (PTC) (n = 171) or follicular thyroid carcinoma (FTC) (n = 85). These operations were performed by means of bipolar forceps coagulation and optical magnification using the technique described previously.7 Of the 171 PTCs, 42 tumors were of the follicular variant of papillary thyroid carcinoma (FVPTC). In keeping with the literature,3 none of the remaining 129 PTCs exhibited a characteristic pattern consistent with insular carcinoma. To create a more homogenous control group, this investigation was limited to the 42 patients with FVPTCs and the 85 patients with FTCs only, resulting in a study population of 127 patients. Of these, 32 patients had undergone primary surgery and 95 patients had undergone reoperations. Patients whose thyroid tumors harbored undifferentiated components were excluded from this investigation.
All surgical specimens had been subjected to pathological analysis and staged according to the current TNM classification (International Union Against Cancer) (except for the distinction by patient age) as stage I, T1N0M0; stage II, T2-4N0M0; stage III, any T N1M0; and stage IV, any TNM1. Insular carcinoma was diagnosed according to the criteria of Carcangiu et al,1 based on evidence of solid clusters (insulae) of small and uniform tumor cells containing a variable number of small follicles. All tumors stained negative for calcitonin. Particular attention was given to the relationship between the thyroid tumor and the surrounding thyroid gland, the adjoining perithyroidal soft tissue, and the surgical margins. From the adjacent soft tissue, every isolated lesion, be it visible or palpable, was embedded separately. Slides were stained with hematoxylin-eosin. Nodal metastases suspected on conventional staining were, in ambiguous cases, confirmed subsequently by cytokeratin and thyroglobulin immunohistochemistry using the standard avidin-biotin complex peroxidase method. In reoperative tumors, pathology reports were obtained from the primary institution to allow for assessment of the T category and primary tumor diameter.
Patients with insular tumors were compared with their noninsular counterparts, who served as controls. Associations between categorical, ordinal, and metric parameters were tested using the 2-tailed Fisher exact test and the Mann-Whitney Wilcoxon rank sum test, respectively. Appropriate adjustments were made using the Bonferroni method. A multivariate logistic regression model was used to examine the relationship between the various clinicopathologic parameters and the insular subtype. The level of significance was set at .05.
A total of 14 (5 FVPTCs, 9 FTCs) insular tumors (11%) were identified among the 127 patients with FVPTC and FTC (Table 1). Of these, 7 were both primary and reoperative tumors. In primary insular tumors, significant correlations were found between median primary tumor diameter (60 mm vs 22 mm; P = .003) and distant metastasis (57% vs 12%; P = .03) relative to noninsular controls. In contrast, reoperative insular tumors exhibited higher T categories (P = .001) and had more frequently occurring nodal metastases (57% vs 18%; P = .03) and distant metastases (71% vs 11%; P = .001) than their noninsular counterparts. When primary and reoperative cases were combined, higher T category (P<.001), greater median tumor diameter (60 vs 25 mm; P = .001), nodal metastasis (50% vs 21%; P = .04), and distant metastasis (64% vs 12%; P<.001) significantly correlated with the insular subtype on univariate analyses. Insular carcinomas did not differ significantly from their noninsular counterparts with regard to demographic factors such as median age of patient at first diagnosis (61 vs 51 years; P = .12) and sex (male, 50% vs 29%; P = .13).
Considering the findings of the univariate analyses (Table 1), a logistic regression analysis was used to identify the individual parameters that correlate with the insular subtype. The following 6 dichotomized variables were initially entered into a multivariate model as independent parameters: primary tumor diameter (>40 mm vs ≤40 mm), extrathyroidal tumor extension (pT4 vs pT1-3), nodal (pN1 vs pN0) and distant metastasis (M1 vs M0), tumor entity (FVPTC vs FTC), and surgical status (primary operation vs reoperation). Of the 127 study patients, 24 patients had to be excluded because of missing information on primary tumor diameter, leaving a total of 103 patients for multivariate analysis. The goodness of fit (93%) of this logistic regression model was not compromised by the withdrawal of surgical status as a parameter from the analysis because extrathyroidal extension (pT4) significantly correlated with surgical status (44% in primary vs 12% in reoperative patients; P = .001). As shown in Table 2, only categorized primary tumor diameter (P = .008) and distant metastasis (P = .003) correlated with the insular subtype. These 2 parameters were interrelated since tumors greater than 40 mm more often (30% vs 8%; P = .008) displayed distant metastasis than tumors measuring 40 mm or less. Neither tumor entity (FVPTC, FTC) nor surgical status (previous operation) were confounding factors in this multivariate analysis (data not shown).
This institutional multivariate analysis provides evidence that the insular subtype of thyroid carcinoma significantly correlates with both categorized primary tumor diameter and distant metastasis but not with extrathyroidal tumor extension (pT4) or nodal metastasis (pN1). In the logistic regression model, distant metastasis was a function of primary tumor diameter since both parameters correlated with each other. This suggests that a hitherto unidentified somatic mutation may induce an accelerated proliferation of the transformed thyrocytes, eventually resulting in the characteristic insular growth pattern and ultimately in enhanced rates of distant metastases with increasing tumor volume. Despite the morphologic heterogeneity and varying quantities of insular carcinoma cells within the concomitant papillary and follicular thyroid tumors,3 ultrastructural and cytopathologic findings support the concept that the growth pattern of insular carcinoma represents a common pathway of dedifferentiation for follicular cell neoplasia of both FTC and PTC types.8,9
The role of these hypothesized genetic events in the unique growth pattern and metastatic potential of insular carcinoma remains to be ascertained. Potential candidate genes for such somatic events are the ras gene family2 or the p53 gene.10 In 5 of 8 cases of insular carcinomas and also in widely invasive FTC, somatic point mutations were detected in the H-RAS and N-RAS histotypes by single-strand conformation polymorphism analysis following amplification by polymerase chain reaction. Intriguingly, 3 of the 5 ras mutations identified in insular carcinoma involved the CAA→AAA transversion at codon 61 (glutamyl transpeptidase domain) of the N-RAS gene.2 Transversion mutations (substitution of a purine for a pyrimidine or vice versa) obviously predominate in undifferentiated thyroid tumors as opposed to transition mutations (substitution of a purine for a purine or a pyrimidine for a pyrimidine), which prevail in differentiated thyroid carcinomas.11 In follicular, poorly differentiated, and undifferentiated thyroid carcinomas, point mutations in the ras oncogene were significantly associated with the appearance of hematogenous metastases (40% vs 6%; P = .03) and bone metastases (54% vs 5%; P = .003) on univariate analysis.12 This observation suggests a role of ras gene activation in the process of distant metastasis. Molecular analysis of exons 5, 6, 7, and 8 of the p53 gene revealed that 14 of 46 insular carcinomas harbored somatic mutations in these exons.10 Considering these molecular data and the current clinicopathologic findings, insular carcinoma seems to represent a subtype rather than an entity in its own right within the spectrum of thyroid tumors. In agreement with this interpretation is the recent view that the insular subtype represents a higher grade of an existing thyroid carcinoma.13 The poorer survival rates in insular carcinoma2,4,14,15 are accounted for by the significant correlation we found between insular carcinoma and distant metastasis. This finding underscores the importance of having an unselected control group and of controlling for primary tumor size and the T, N, and M categories.
The surgical strategy for insular carcinoma should aim at achieving local control. To this end, a systematic dissection of the cervicocentral lymph nodes is advocated,6,16 since approximately half of insular carcinoma cases display nodal metastases by the time of diagnosis according to the literature2,15 and our data (Table 1). In view of the high rates and prognostic significance of lung and bone metastases in this condition2,4,6,14,17,18—in this series, 7 and 5 of 14 patients, respectively—all patients should undergo early postoperative scintigraphy.17,18 When distant metastases appear on scintigraphy, 131I radioiodine therapy should be initiated for distant control.19 A similar approach should be pursued in children and adolescents.18,20 Bone metastasis of the vertebral column may require palliative stabilization to keep the involved vertebral body from collapsing and impinging on the spinal cord to prevent transverse palsy, which could not only decrease quality of life, but overall survival. This was the case in one of our patients who had been followed up at an outside institution for vertebral metastasis of an insular thyroid carcinoma. While radioiodine therapy may occasionally cure patients with insular thyroid carcinoma and pulmonary metastases,18 dedifferentiated clones of distant metastases will evolve in some patients following several courses of radioiodine treatment. In this series, one such instance was noted in 14 patients with insular carcinoma. These tumors are particularly challenging because of their failure to take up radioiodine. The role of chemotherapy is questionable since insular carcinomas are frequently unresponsive to most cytotoxic agents in vitro and in vivo.21
Corresponding author and reprints: Andreas Machens, MD, Department of General Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strabe 40, D-06097 Halle/Saale, Germany (e-mail: email@example.com).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 23
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.